Alendronate Sodium Tablet
Product Images NDC 50090-3126

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-3126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Alendronate Fig1)

Figure 1 (Alendronate Fig1)
FDA Label Image

Figure 2 (Alendronate Fig2)

Figure 2 (Alendronate Fig2)
This is a table showing the increase in bone mineral density (BMD) in postmenopausal women with osteoporosis after three years of treatment with Alendronate 10 mg/day. The BMD increase is listed as a mean percentage increase relative to placebo and is shown for three different areas of the body: the lumbar spine, femoral neck, and trochanter. The table also includes reference numbers, but they are not readable due to errors.*
FDA Label Image

Figure 3 (Alendronate Fig3)

Figure 3 (Alendronate Fig3)
Description: This appears to be a graph from a study on Osteoporosis treatment in postmenopausal women. The graph compares the effect of alendronate 10mg/day versus a placebo on Lumbar Spine BMD Percent Change From Baseline over a period of 36 months. However, the information provided is limited and difficult to interpret without further context.*
FDA Label Image

Figure 4 (Alendronate Fig4)

Figure 4 (Alendronate Fig4)
FDA Label Image

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)

Studies In Glucocorticoid (Treated Patients Increase in BMD Alendronate 5 mg/day at One Year)
FDA Label Image

Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)

Studies In Paget's Disease Of Bone Effect On Serum Alkaline Phosphatase Of Alendronate 40 mg/day Versus Placebo Or Etidronate 400 mg/day (Alendronate Fig6)
This document presents the effect of Alendronate 40 mg/day on serum alkaline phosphatase in patients with Paget's Disease of Bone in comparison to Placebo or Etidronate 400 mg/day, based on multinational and U.S. studies. It includes a graph showing the mean % change from baseline over a period of 6 months.*
FDA Label Image

Chemical Structure (Alendronate Str)

Chemical Structure (Alendronate Str)
FDA Label Image

Label Image (Lbl500903126)

Label Image (Lbl500903126)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.